These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30189807)

  • 61. Bioequivalence of topical generic products. Part 1: Where are we now?
    Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C
    Eur J Pharm Sci; 2018 Oct; 123():260-267. PubMed ID: 30053463
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
    Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):944-52. PubMed ID: 27102378
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bioequivalence and narrow therapeutic index drugs.
    Benet LZ; Goyan JE
    Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Drug substitution in transplantation.
    First MR; Gober AO; Olyaei A
    Am J Kidney Dis; 1999 Jul; 34(1):205-6. PubMed ID: 10401039
    [No Abstract]   [Full Text] [Related]  

  • 65. [Branded drugs and generics: an ambiguity of choice].
    Rudakova AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(6):32-4. PubMed ID: 22983235
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Particle Size Distribution Equivalency as Novel Predictors for Bioequivalence.
    Ngeacharernkul P; Stamatis SD; Kirsch LE
    AAPS PharmSciTech; 2018 Oct; 19(7):2787-2800. PubMed ID: 30117041
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Generic drugs, bioavailability, and bioequivalence].
    Palma-Aguirre JA
    Gac Med Mex; 1998; 134(4):491-4. PubMed ID: 9789395
    [No Abstract]   [Full Text] [Related]  

  • 68. Clinical Endpoint Bioequivalence Studies Are Not Sensitive: A Perspective From Generic Drugs.
    Novakovic J; Szirtes J; Fields A; Tsang YC
    Clin Pharmacol Ther; 2019 Feb; 105(2):295-297. PubMed ID: 30456787
    [No Abstract]   [Full Text] [Related]  

  • 69. Application of the 3Rs principles in the development of pharmaceutical generics.
    Vichare AS; Kamath SU; Leist M; Hayes AW; Mahadevan B
    Regul Toxicol Pharmacol; 2021 Oct; 125():105016. PubMed ID: 34302895
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
    Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antiepileptic drugs: the drawbacks of generic substitution.
    Lancet Neurol; 2010 Mar; 9(3):227. PubMed ID: 20170834
    [No Abstract]   [Full Text] [Related]  

  • 73. When do differences in dissolution profiles predict clinical problems?
    Ngo SN
    J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660
    [No Abstract]   [Full Text] [Related]  

  • 74. [Generic drugs, a matter of bioequivalence].
    Palma Morgado D; Domínguez Camacho JC
    Farm Hosp; 2007; 31(2):73-4. PubMed ID: 17590114
    [No Abstract]   [Full Text] [Related]  

  • 75. Is bioavailability altered in generic versus brand anticonvulsants?
    Jankovic SM; Ignjatovic Ristic D
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):329-32. PubMed ID: 25440299
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
    Birnbaum R
    JAMA; 1997 Sep; 278(11):897-8; author reply 898-900. PubMed ID: 9302239
    [No Abstract]   [Full Text] [Related]  

  • 77. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
    Lankin KM
    JAMA; 1997 Sep; 278(11):897; author reply 898-900. PubMed ID: 9302238
    [No Abstract]   [Full Text] [Related]  

  • 78. Establishment of in vitro-in vivo equivalence of highly variable drugs - a generic product development perspective.
    Pathak SM; Aggarwal D; Venkateswarlu V
    Pharm Dev Technol; 2014 Jun; 19(4):401-10. PubMed ID: 23607272
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
    Bell BM
    JAMA; 1997 Sep; 278(11):896; author reply 898-9. PubMed ID: 9302234
    [No Abstract]   [Full Text] [Related]  

  • 80. Converging Generic Drug Product Development: Bioequivalence Design and Reference Product Selection.
    Charoo NA
    Clin Pharmacokinet; 2020 Nov; 59(11):1335-1355. PubMed ID: 32757104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.